Moleculin Biotech Inc (NASDAQ:MBRX) is a preclinical pharmaceutical provider that deals in the development of anti-cancer drug candidates. Some of these anti-cancer drug candidates have their basis on license agreements with The University of Texas System.

Today, the top provider has made an announcement revealing that it has asked Theradex Systems, Inc, which is its contract research organization (CRO) to expand its engagement in order to include clinical sites in Poland for Moleculin’s planned Phase I/II clinical trial of Annamycin to help offer treatment for the relapsed or refractory acute myeloid leukemia (AML).

Chairman and CEO of Moleculin, Walter Klemp while recently addressing a number of top news reporters said, “We have been working on ways to increase our rate of patient accrual once we start our planned clinical trial for Annamycin and we have identified several promising sites in Poland. By expanding our engagement with Theradex, we help ensure tight coordination of clinical activity between the US and Poland. “If our IND is permitted, which must happen for clinical trials to begin, we intend to hit the ground running, and we believe Poland improves that capability.”

According to the latest reports, it has been revealed that the AML patients in Poland have been experiencing more problems in terms of accessing clinical trials as compared to those patients in the US. Mr. Klemp has said that this mere fact should make it easier for the company to move ahead to recruit relapsed or refractory AML patients.

 Those patients that have received a fewer number of prior failed treatments according to will most probably stick out as the ones less resistant to treatments in future and at the same time the ones whose health is less severely compromised. There are plans underway to find one lead European Principal Investigator. On top of this, there will also be the identification of the most appropriate clinical sites that will be lined up for major expansions.